Nyxoah (NYXH) Stock Overview
A medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
NYXH Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Nyxoah SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.94 |
| 52 Week High | €11.15 |
| 52 Week Low | €3.84 |
| Beta | 0.60 |
| 1 Month Change | -28.88% |
| 3 Month Change | -39.10% |
| 1 Year Change | -50.25% |
| 3 Year Change | -39.76% |
| 5 Year Change | -79.79% |
| Change since IPO | -79.79% |
Recent News & Updates
Recent updates
FDA Approval Will Launch Genio And Expand Global Reach
Imminent FDA approval of Genio could significantly boost revenues and market penetration in the U.S., driven by robust clinical results and strategic recruitment.It's Probably Less Likely That Nyxoah S.A.'s (EBR:NYXH) CEO Will See A Huge Pay Rise This Year
Jun 05
Rock star Growth Puts Nyxoah (EBR:NYXH) In A Position To Use Debt
Jan 24Do Insiders Own Lots Of Shares In Nyxoah S.A. (EBR:NYXH)?
Dec 21Shareholder Returns
| NYXH | BE Medical Equipment | BE Market | |
|---|---|---|---|
| 7D | -2.7% | -1.3% | -0.05% |
| 1Y | -50.3% | -5.2% | 3.8% |
Return vs Industry: NYXH underperformed the Belgian Medical Equipment industry which returned -5.2% over the past year.
Return vs Market: NYXH underperformed the Belgian Market which returned 3.8% over the past year.
Price Volatility
| NYXH volatility | |
|---|---|
| NYXH Average Weekly Movement | 8.5% |
| Medical Equipment Industry Average Movement | 5.3% |
| Market Average Movement | 3.2% |
| 10% most volatile stocks in BE Market | 6.5% |
| 10% least volatile stocks in BE Market | 1.9% |
Stable Share Price: NYXH's share price has been volatile over the past 3 months compared to the Belgian market.
Volatility Over Time: NYXH's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 184 | Olivier Taelman | www.nyxoah.com |
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah SA Fundamentals Summary
| NYXH fundamental statistics | |
|---|---|
| Market cap | €159.10m |
| Earnings (TTM) | -€77.20m |
| Revenue (TTM) | €4.93m |
Is NYXH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NYXH income statement (TTM) | |
|---|---|
| Revenue | €4.93m |
| Cost of Revenue | €1.71m |
| Gross Profit | €3.22m |
| Other Expenses | €80.42m |
| Earnings | -€77.20m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 13, 2025
| Earnings per share (EPS) | -2.06 |
| Gross Margin | 65.27% |
| Net Profit Margin | -1,564.91% |
| Debt/Equity Ratio | 26.1% |
How did NYXH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/25 17:46 |
| End of Day Share Price | 2025/09/25 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nyxoah SA is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| Michael Polark | Baird |
| Ross Osborn | Cantor Fitzgerald & Co. |